First Clinical Use of ES Cells
Gujarat, India -
To our knowledge the first-ever peer-reviewed publication describing clinical use of embryonic stem cells has appeared this week in the journal Transplantation Proceedings (Trivedi et al. Embryonic stem cell derived and adult hematopoietic stem cell transplantation for tolerance induction in a renal allograft recipient:-a case report.Transplant Proc. 2006 Nov;38(9):3103-8).
This paper describes a case report of tolerance induction in a male kidney transplant recipient, in which donor bone marrow (from his sister) was "superpotentiated" by the co-administration of embryonic stem cells generated from the sister that were administered with the bone marrow.
The recipient appeared healthy at 100 days post procedure and did not require immune suppression, which is a fundamental advancement in the field of transplant immunology.
Careful reading of the paper reveals that the investigators "threw the kitchen sink" in terms of trying to induce tolerance, besides using the embryonic stem cells, they used procedures such as intrathymic donor marrow administration, intrabone bone marrow administration, and donor lymphocyte infusion.
We at StemCellPatents.com urge cause in the use of embryonic stem cells due to their carcinogenic potential. Despite this, the experiment described as already been performed and much can be learned from examining them.
Social & Bookmarking:
8 Comments | Add Comment
Paul said...
Well allo transplant is allo transplant, even if matched at HLA rejection still occurs... but to risk teratoma... i really wonder what will happen to this patient..and what kind of reputable journal would report on this????
Paul
notch1 said...
journal what published this paper is Transplantation Proceedings (Elsevier Science)
and this is pretty good journal in transplantation topic
paper web-link
yea i agree alot of questions this paper arised:
for example i don't like their protocols for HSC differentiation induction from ES - just total BM coculture without any cytokines for 2 days,
i'm pretty sure that more then half cells in transplant were ESC, only 7 percent CD34+ and 66 percent CD45+
we can not exclude contamination of BM cells in transplant because they were cocultured
follow up described in paper = 100 days and no tumor formation report,
interesting...
Paul Nagourney said...
Here is the author contacts... somebody contact him...maybe we can have him interviewed on StemCellPatents.com !!!!
H.L. Trivedi, Institute of Transplantation
Sciences, Department of Nephrology and Transplantation
Medicine, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat
380016, India.
E-mail: ikdrcad1 at sancharnet dot in
Denis said...
ok, thanks.
renuve e-mail, becouse thay have more SPAM
thanks a lot
Michael said...
Hey Denis, when you contact Trivedi ask him why he didnt try to make mesenchymals from the ES cells. These are more tolerogenic than straight hematopoietic stem cells
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.
notch1 said...
just read this paper,
this is realy FIRST REPORT about hESC or their derivates infusion into human!
Authors cultured ESC in "hematopoietic" condition only for a 2 days and final of CD34+ before transplantation was only 7.6
so other 92 are undifferentiated ES? it's seem to get a highiest risk of teratoma formation after...
But nothing about complications here,
i just interested about oucome of this transplantation
and secondly if renal transplant was 6/6 HLA matched,, how authors can say about tolerance induction caused hematopoietic-derived ES transplantation?